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Translational control of depression-like behavior
via phosphorylation of eukaryotic translation
initiation factor 4E
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Gustavo Turecki 3,5, Jean-Claude Lacaille 2, Gabriella Gobbi3 & Nahum Sonenberg1
Translation of mRNA into protein has a fundamental role in neurodevelopment, plasticity, and
memory formation; however, its contribution in the pathophysiology of depressive disorders
is not fully understood. We investigated the involvement of MNK1/2 (MAPK-interacting
serine/threonine-protein kinase 1 and 2) and their target, eIF4E (eukaryotic initiation factor
4E), in depression-like behavior in mice. Mice carrying a mutation in eIF4E for the MNK1/2
phosphorylation site (Ser209Ala, Eif4e ki/ki), the Mnk1/2 double knockout mice (Mnk1/2
−/−), or mice treated with the MNK1/2 inhibitor, cercosporamide, displayed anxiety- and
depression-like behaviors, impaired serotonin-induced excitatory synaptic activity in the
prefrontal cortex, and diminished ﬁring of the dorsal raphe neurons. In Eif4e ki/ki mice, brain
IκBα, was decreased, while the NF-κB target, TNFα was elevated. TNFα inhibition in Eif4e ki/ki
mice rescued, whereas TNFα administration to wild-type mice mimicked the depression-like
behaviors and 5-HT synaptic deﬁcits. We conclude that eIF4E phosphorylation modulates
depression-like behavior through regulation of inﬂammatory responses.
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Major depressive disorder (MDD) is one of the leadingcauses of disability worldwide1, with a lifetime pre-valence of 16.6 % in the United States2. Current treat-
ments are ineffective in about one third of patients3, indicating
the urgent need to better understand MDD pathophysiology and
identify novel therapeutic targets. The MAPK/ERK pathway is
impaired in the brains of MDD patients4,5, however a causal role
for downstream mRNA translation in depression has not been
studied. mRNA translation (protein synthesis) plays a major role
in the control of gene expression, allowing for rapid and spatially
restricted changes in protein levels6. A rate-limiting step in the
initiation of mRNA translation is the recruitment of the eukar-
yotic initiation factor 4E (eIF4E) to the mRNA 5′cap structure
(m7GpppN, where N is any nucleotide). eIF4E binds to the
scaffolding protein eIF4G, which also binds to the RNA helicase
eIF4A, to form the eIF4F complex, which mediates the recruit-
ment of preinitiation complex6. eIF4E is a target of the mam-
malian target of rapamycin complex 1 (mTORC1) and MAPK/
ERK pathways;7 the activation of which stimulates protein
synthesis.
The MAP kinases ERK1/2 and p38 control mRNA translation
through the MAPK-interacting serine/threonine-protein kinase 1
and 2 (MNK1/2). MNKs phosphorylate eIF4E8 on Ser2099–11.
Phosphorylation of eIF4E engenders increased translation of a
subset of mRNAs12, some of which play a role in memory for-
mation13 and regulation of circadian rhythms14.
In MDD-suicide subjects, the activity, protein, and mRNA
levels of ERK1/2 are decreased in post-mortem prefrontal and
hippocampal areas4,5. The consequence of reduced activation of
ERK1/2 in the pathophysiology of depression and on the anti-
depressant effect of selective serotonin reuptake inhibitors (SSRIs)
15,16 and mood stabilizers17 is well understood. In this regard,
MAPK kinase (MEK) inhibition induces depression-like beha-
viors and blocks the antidepressant action of SSRIs and tricyclic
compounds15. Furthermore, reduction in P38 MAPK phosphor-
ylation has been observed in an animal model of depression and
aggressive behavior, induced by dietary deprivation of n-3 poly-
unsaturated fatty acids18. Also, P38 MAPK activation contributes
to the induction of depression-like behavior by chronic stress and
immune mediators19,20.
Here we demonstrate that genetic and pharmacological inhi-
bition of eIF4E phosphorylation in mice resulted in a depression-
like state, impaired serotonin excitatory activity in the prefrontal
cortex, and diminished ﬁring of raphe serotonergic neurons.
Inhibition of eIF4E phosphorylation caused decreased translation
of IκBα (nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha) mRNA in the brain. Decreased IκBα, a
repressor of the transcription factor NF-κB, led to increased
expression of the cytokine TNFα and exacerbated microglial
responsiveness to inﬂammatory stimuli with lipopolysaccharide
(LPS). Increased inﬂammation in the brain is a hallmark of several
psychiatric disorders, including MDD19,21, in which patients have
elevated cytokine levels22,23, and microgliosis24. Increased per-
ipheral and central inﬂammatory markers in MDD are thought to
contribute to the pathophysiology and treatment responsive-
ness19,21. Importantly, inhibition of TNFα ameliorated the
depression-like behavior, as well as serotonergic synaptic and cell
ﬁring alterations induced by the lack of eIF4E phosphorylation.
Results
The MNK1/2-eIF4E pathway controls depression-like beha-
viors. To study the role of eIF4E phosphorylation in depression
pathophysiology, we examined the Mnk1 and Mnk2 double
knock-out (Mnk1/2−/−)11, and the Eif4e Ser209Ala knock-in
(Eif4e ki/ki)12 mice in several validated paradigms for depression-
like behavior. In the forced swim test (FST), immobility time was
increased in male (M) and female (F) Mnk1/2−/− (by 28.1 ± 13.6
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Fig. 1 Genetic inhibition of eIF4E phosphorylation induced anxiety- and depression-like behaviors. a Male (M) and female (F) mice mutant for the genes
encoding MNK1 and MNK2 (Mnk1/2−/− mice) and their wild-type littermates (Mnk1/2+/+) were assessed for despair-like behavior in the forced swim test
(FST) (M, n= 8 Mnk1/2+/+, n= 9 Mnk1/2−/−; F, n= 3 Mnk1/2+/+, n= 9 Mnk1/2−/−). b Male and female mice bearing a mutation in the Eif4e gene
(Ser209 was substituted to Ala, Eif4e ki/ki) were also tested in the FST (M, n= 19 Eif4e+/+, n= 19 Eif4e ki/ki; F, n= 7 Eif4e+/+, n= 8 Eif4e ki/ki). c
Novelty suppressed feeding (NSF) was assessed in Mnk1/2−/− (M, n= 9; F, n= 10) and wild-type mice (M, n= 8; F, n= 10). d NSF was also assayed in
Eif4e+/+ and ki/ki mice (M, n= 9 Eif4e+/+, n= 9 Eif4e ki/ki; F, n= 8 Eif4e+/+, n= 9 Eif4e ki/ki). e Latency to feed in the home cage (home cage feeding,
HCF) was determined in the Mnk1/2−/− and f Eif4e ki/ki mice and their littermates. g Time spent in the center of an open ﬁeld (OF) arena was measured in
Mnk1/2−/− (M, n= 12 Mnk1/2+/+, n= 8 Mnk1/2−/−; F, n= 7 Mnk1/2+/+, n= 13 Mnk1/2−/−) and h Eif4e ki/ki mice and their littermates (M, n= 17 Eif4e
+/+, n= 18 Eif4e ki/ki; F, n= 11 Eif4e+/+, n= 19 Eif4e ki/ki). i Locomotion was also measured in Mnk1/2−/− and j Eif4e ki/ki mice. ** p < 0.01, *** p < 0.001
vs. wild-type littermates (see Supplementary Table 2 for detailed results of statistical tests)
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s in M and 56.5 ± 18.7 s in F mice) and Eif4e ki/ki mice (by 30.4 ±
10.9 s in M and 40.0 ± 17.3 s in F) (Fig. 1a, b). Male Mnk1/2−/−
and Eif4e ki/ki mice were more immobile than wild-type in the
tail suspension test (by 70.2 ± 27.5 s and 35.8 ± 12.0 s, respec-
tively) (Supplementary Fig. 1a, b). This test could not be accu-
rately assessed in females, since a large proportion climbed on
their own tails while suspended, as previously reported25.
In the novelty-suppressed feeding (NSF) test, a measure of
hyponeophagia that is responsive to chronic treatment with
antidepressants26,27, the latency to feed in a novel context was
increased in male Mnk1/2−/− (by 73.3 ± 23.4 s) and Eif4e ki/ki
(by 156.1 ± 56.7 s), as well as female Eif4e ki/ki mice as compared
to control littermates (by 128.5 ± 57.4 s) (Fig. 1c, d). The mutant
mice did not differ in the latency to feed in their home cage as
compared to wild-type (HCF, Fig. 1e, f). In contrast, the female
Mnk1/2−/− were not affected in the latency to feed in the novel
context (Fig. 1c) but exhibited a decreased latency to feed in the
home cage of 14.8 ± 5.7 s (Fig. 1e). This suggests a female-speciﬁc
role in feeding behavior for MNK1/2, independent of eIF4E
phosphorylation.
Next, we tested exploratory behavior in the open ﬁeld. Both
male and female Mnk1/2−/− and Eif4e ki/ki mice showed a
decrease in the time spent in the center of the arena (Mnk1/2−/−:
by 69.6 ± 21.4 s in M and 67.7 ± 22.0 s in F; Eif4e ki/ki: by 46.4 ±
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Fig. 2 Serotonergic dysfunction in Eif4e ki/ki mice. a Representative whole cell recordings of spontaneous excitatory post-synaptic currents (sEPSCs) from
layer V pyramidal neurons of the medial prefrontal cortex (mPFC) of wild-type and Eif4e ki/ki mice. Traces represent consecutive recordings of synaptic
currents before (baseline) and after 5-HT (20 μM) treatment from single pyramidal cells in each group. b Frequency of sEPSCs from pyramidal neurons of
wild-type and Eif4e ki/ki mice before (−) and after 5-HT at 20 μM (n= 7 cells from 5 Eif4e+/+; n= 8 cells from 7 Eif4e ki/ki), 50 μM (n= 4 cells from 3
Eif4e+/+; n= 5 cells from 3 Eif4e ki/ki) or 100 μM (n= 5 cells from 3 Eif4e+/+; n= 6 cells from 3 Eif4e ki/ki). c In vivo single-unit extracellular recordings
of dorsal raphe neurons were performed in anesthetized Eif4e+/+and ki/ki mice. d Firing rate of dorsal raphe 5-HT neurons, measured in Eif4e+/+and ki/ki
mice (n= 56 single unit recordings from 8 Eif4e+/+mice; n= 43 single unit recordings from 7 Eif4e ki/ki mice). e 5-HT neurons recorded per descent
(track) in the dorsal raphe of wild-type and Eif4e ki/ki mice (n= 8 Eif4e+/+mice; n= 7 Eif4e ki/ki mice). f Firing rate of non-5-HT neurons in the DR (n=
27 single unit recordings from 6 Eif4e+/+mice; n= 16 single unit recordings from 5 Eif4e ki/ki mice). g Number of non-5-HT neurons per descent in the DR
(n= 6 Eif4e+/+mice; n= 5 Eif4e ki/ki mice). h Number of NeuN+ cells in the DR nuclei, which was subdivided into DR dorsal part (DRD), DR lateral part
(DRL), posterodorsal raphe nucleus (PRN), and DR ventral part (DRV). Data are means of 4 slides per animal (n= 4 Eif4e+/+mice; n= 5 Eif4e ki/ki mice). i
Number of tryptophan hydroxylase 2 (TPH2) positive cells in the DRN. j Representative images of the DR IHC; blue: nuclear DAPI staining; red: TPH2;
green: NeuN. Scale bar is 100 μM. * p < 0.05, *** p < 0.001 vs. wild-type littermates (see Supplementary Table 2 for detailed results of statistical tests)
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12.1 s in M and 36.6 ± 13.6 s in F) (Fig. 1g, h). While no changes
in locomotion were observed in Eif4e ki/ki mice compared to
their control littermates (Fig. 1j), the Mnk1/2 mice showed
decreased locomotion (by 717.8 ± 214 s in M and 990 ± 219.8 s in
F; Fig. 1i). A second exposure to the open ﬁeld abrogated the
difference in locomotion between Mnk1/2−/− and wild-type mice
(Supplementary Fig. 1c–e). However, the difference in time spent
in the center of the ﬁeld persisted (Supplementary Fig. 1d–f),
suggesting that novelty-related anxiety, rather than hypo-activity,
caused decreased locomotion during the 1st exposure to the open
ﬁeld in the Mnk1/2−/− mice. Taken together, these results
demonstrate that reduction of eIF4E phosphorylation, either by
knocking out the Mnk1 and Mnk2 genes or by mutating the
phosphorylation site in Eif4e, elicits depression- and anxiety-like
behaviors.
eIF4E phosphorylation controls 5-HT neurotransmission. To
understand the synaptic mechanisms underlying the depression-
like state caused by inhibition of eIF4E phosphorylation, we ﬁrst
focused on serotonin (5-HT) neurotransmission in the medial
prefrontal cortex (mPFC), a brain region central in depression
pathophysiology28–30. Using whole-cell recording from layer V
pyramidal neurons, we found no difference in the frequency of
spontaneous excitatory postsynaptic current (sEPSCs) between
wild-type and Eif4e ki/ki mice in baseline conditions (Fig. 2a,b).
5-HT stimulates sEPSCs in layer V pyramidal neurons31,
mediated by excitatory 5-HT2A postsynaptic receptors32–34. 5-HT
(20 μM) augmented the frequency of sEPSCs in wild type by
84.55 ± 24.09 %, but not in Eif4e ki/ki mice (Fig. 2a, b). The
NMDA-blocker and rapidly-acting antidepressant, ketamine,
enhances 5-HT-induced sEPSCs35. We therefore tested whether
the enhancement occurs in Eif4e ki/ki mice. After a single
injection of ketamine (IP, 10 mg/kg) 24 h prior to recording,
5-HT increased the frequency of sEPSCs by 336.80 ± 64.88%
over baseline in wild-type but not in Eif4e ki/ki mice
(Supplementary Fig. 4a, b). In either condition, there were no
changes in sEPSC rise and decay time (Supplementary Fig. 2b and
4d, e), and amplitude (Supplementary Fig. 2a and 4c), except for
an increase in sEPSC decay time by 5-HT in saline-treated Eif4e
wild-type and ki/ki mice (Supplementary Fig. 2c). To determine
whether a greater dose of 5-HT would stimulate sEPSC in Eif4e
wild type and ki/ki mice, we treated layer V mPFC slices with 50
and 100 μM of 5-HT. While both doses were excitatory in control
mice, only the 100 μM dose induced an increase in sEPSC fre-
quency as compared to that of control mice (Fig. 2b and Sup-
plementary Fig. 2d, e). These results indicate that the depression-
like phenotypes in Eif4e ki/ki mice are associated with decreased
sensitivity to 5-HT excitatory neurotransmission in layer V
mPFC.
Serotonergic neurons that innervate the mPFC reside in the
dorsal raphe (DR) nuclei36. We thus determined whether the
activity of DR neurons is affected in Eif4e ki/ki mice. To this end,
we performed in vivo single-unit extracellular recordings of DR
neurons37 (Fig. 2c). Male and female Eif4e ki/ki had a 36.19 ± 6.54
and 40.87 ± 16.27% decrease, respectively, in the ﬁring rate of
electrophysiologically deﬁned 5-HT neurons compared to control
littermates, respectively (Fig. 2d and Supplementary Fig. 3c), in
the absence of changes in the number of spontaneously active
neurons (neurons per descent; Fig. 2e and Supplementary Fig. 3d).
Furthermore, the ﬁring rate and number of non-5-HT neurons in
DR was the same between genotypes (Fig. 2f, g). To determine
whether the decreased ﬁring rate of DR neurons was due to
increased activity of the 5-HT1A inhibitory autoreceptor38, DR
neurons were recorded at baseline and following the administra-
tion of the 5-HT1A antagonist, WAY-100635 (IP, 0.1-0.3 mg/kg).
The latter induced a similar dose-dependent increase in DR
neuron ﬁring rate in wild-type and Eif4e ki/ki mice (Supplemen-
tary Fig. 3a, b), suggesting that the 5-HT1A autoreceptors do not
contribute to the diminished spontaneous activity of DR neurons
in Eif4e ki/ki mice. These results indicate that reduction of eIF4E
phosphorylation impaired serotonergic DR neuron ﬁring and 5-
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Fig. 3 Normal response to Fluoxetine in Eif4e ki/ki mice. a Male wild-type and Mnk1/2−/− mice were treated with saline or ﬂuoxetine (IP, 3 mg kg−1)
and tested in the FST after 30min (n= 7 Mnk1/2+/+Saline, n= 9 Mnk1/2−/− Saline; n= 10 Mnk1/2+/+Fluoxetine, n= 10 Mnk1/2−/− Fluoxetine). b Male
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HT post-synaptic excitation in the mPFC, in a manner similar to
depression-inducing chronic stress31,39.
To determine whether the number of DR 5-HT neurons was
altered in Eif4e ki/ki mice, we used tryptophan hydroxylase 2
(TPH2) as a histological marker. The number of TPH2+ cells
was decreased in two subregions of the DR, the ventral part
(DRV) and the posterodorsal raphe nucleus (PDR, Fig. 2h, j),
while the total number of neurons (NeuN+ cells) was the same
between genotypes (Fig. 2i, j). When expressed as percent of the
total neuronal population, the difference was only evident in the
PDR (10.71 ± 1.039 vs 6.637 ± 1.179 % of NeuN+ cells in PDR),
suggesting a restricted reduction in 5-HT neurons in Eif4e ki/ki
mice. These results are in agreement with the unchanged number
of spontaneously active 5-HT neurons observed in in vivo
electrophysiology (Fig. 2e and Supplementary Fig. 3d).
The ﬁnding of impaired serotonergic neurotransmission
prompted us to investigate the behavioral response of Mnk1/2−/−
and Eif4e ki/ki mice to the SSRI, ﬂuoxetine. Acute treatment with
ﬂuoxetine (IP, 3 mg kg−1, 30 min) induced a signiﬁcant decrease
in immobility in the FST in both Mnk1/2−/− and their wild-type
littermates by 46.88 ± 9.52 % and 62.83 ± 27.23 %, respectively
(Fig. 3a). Fluoxetine also reduced immobility in Eif4e+/+and
ki/ki mice by 43.00 ± 16.85 % and 47.03 ± 10.75 %, respectively
(Fig. 3b). Importantly, neither acute (IP, 3 mg kg−1, 0.5 h)
nor chronic (IP, 14 × 10 mg kg−1) ﬂuoxetine, or repeated (IP, 3 × ,
10 mg kg−1) citalopram treatment changed the phosphorylation
of eIF4E in the brain of wild-type mice (Fig. 3c, e). Similarly,
ketamine treatment (IP, 10 mg kg−1, 1 h) did not change
eIF4E phosphorylation in wild-type mice (Supplementary
Fig. 4g–i), although it reduced immobility in the FST in both
Eif4e ki/ki and their wild-type littermates (Supplementary Fig. 4f).
These results indicate that these treatments do not engage
the MNK1/2-eIF4E signaling pathway to induce anti-depressant-
like effects.
0 20
0
50
100
150
Cercosporamide
(mg kg–1)
a
T
im
e 
im
m
ob
ile
(s
)
0 20
Cercosporamide
(mg kg–1)
p-
eI
F
4E
 / 
eI
F
4E
*
Mnk1
Mnk2
eIF4E
Cercosporamide S209
0 20
Cercosporamide
(mg kg–1)
p-eIF4E
eIF4E
GAPDH
db c
*
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
0 20
Cercosporamide
(mg kg–1)
eI
F
4E
 / 
G
A
P
D
H
0 20
0
1
2
3
F
iri
ng
 r
at
e 
(H
z)
Cercosporamide
(mg kg–1)
**
**
***
ns
Eif4e +/+ Eif4e ki/ki
0 20
0
1
2
3
N
eu
ro
ns
 p
er
 tr
ac
k
Cercosporamide
(mg kg–1)
– 5-HT
0
4
8
12
+/+ 0 mg kg–1
+/+ 20 mg kg–1
sE
P
S
C
 fr
eq
ue
nc
y
(H
z)
gf
– 5-HT
0
4
8
12
ki/ki 0 mg kg–1
ki/ki 20 mg kg–1
sE
P
S
C
 fr
eq
ue
nc
y
(H
z)
&
Baseline 5-HT
Eif4e +/+
Eif4e ki/ki
Baseline 5-HT
0 mg kg–1 20 mg kg–1Cercosporamidee
250 ms
25 pA
25 kDa
25 kDa
37 kDa
Fig. 4 Pharmacological inhibition of MNK1/2 induces despair-like behavior and 5-HT synaptic impairments. a Cercosporamide, an MNK1 and MNK2
inhibitor, was administered for 5 consecutive days to wild-type mice (IP, 20mg kg−1). b Representative western blot images for phosphorylated eIF4E (p-
eIF4E), total eIF4E and GAPDH in the cortex-hippocampus of mice treated with vehicle or cercosporamide. c Average levels of p-eIF4E in vehicle and
cercosporamide-treated wild-type mice (vehicle (0 mg kg−1), n= 7; cercosporamide, n= 7). d Cercosporamide administration induced increased
immobility in the Forced Swim Test (FST) in wild-type mice (vehicle (0mg kg−1), n= 8; cercosporamide, n= 7). e Representative sEPSC traces from
recordings in layer V mPFC from wild-type or Eif4e ki/ki mice treated with vehicle or cercosporamide. f Layer V mPFC sEPSC frequency of wild-type (left
panel, vehicle n= 5 neurons from three mice, cercosporamide n= 6 neurons from two mice) or Eif4e ki/ki mice (right panel, vehicle n= 5 neurons from 2
mice, cercosporamide n= 7 neurons from 3 mice) treated with vehicle or cercosporamide. g Firing rate of 5-HT DR neurons in wild-type and Eif4e ki/ki
mice treated with vehicle or cercosporamide (Eif4e+/+: Vehicle 33 neurons from 6 mice, cercosporamide 22 neurons from 10 mice; Eif4e ki/ki: vehicle 22
neurons from 4 mice, cercosporamide 18 neurons from 4 mice). * p < 0.05, ** p < 0.01, ***p < 0.001 vs vehicle-treated wild-type mice; & p < 0.05 vs. saline-
treated Eif4e+/+ (see Supplementary Table 2 for detailed results of statistical tests)
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We also determined that adult hippocampal progenitor
proliferation (Ki67+ cells, Supplementary Fig. 5a, b), survival
(BrdU+ cells, 28 d after treatment, Supplementary Fig. 5c, d) and
differentiation (DCX+ cells, Supplementary Fig. 5e, f) was not
changed in male and female Eif4e ki/ki mice.
Inhibition of MNK1/2 induces depression-like phenotypes. To
rule out developmental/compensatory mechanisms in the
depression- and anxiety-like behaviors in Mnk1/2−/− and Eif4e
ki/ki mice, we examined whether the depression-like behavior
could be induced by pharmacological inhibition of MNK1 and 2
in adult wild-type mice using cercosporamide, an inhibitor of
MNK1 and MNK240 (Fig. 4a). Systemic administration of cer-
cosporamide (IP, 5 × 20 mg kg−141) decreased eIF4E phosphor-
ylation in the brain by 44.18 ± 14.76 % (Fig. 4b, c), and enhanced
immobility in the FST by 33.49 ± 12.66 s (Fig. 4d).
Furthermore, in wild-type mice cercosporamide also inhibited
the excitatory response of 5-HT in layer V mPFC pyramidal
neurons (Fig. 4e, f) and decreased the ﬁring rate of 5-HT DR
neurons (Fig. 4g). Importantly, cercosporamide failed to change
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any of these parameters in Eif4e ki/ki mice (Fig. 4e, g), indicating
an effect through eIF4E phosphorylation and not via unknown
MNK1/2 targets. These results strongly support a direct role of
eIF4E phosphorylation in the pathophysiology of depression.
Dysregulated TNFα synthesis in the brain of Eif4e ki/ki mice.
To gain insight into the molecular mechanism by which the
lack of eIF4E phosphorylation results in depression-like behavior
and altered serotonergic neurotransmission, we inspected the list
of mRNAs whose translation is signiﬁcantly reduced in the
absence of eIF4E phosphorylation12. Among these, the Nfkbia
mRNA, encoding for the negative regulator of NF-κB, IκBα, is of
particular interest12,42 because of the prominent role of inﬂam-
matory mechanisms in the pathophysiology of MDD and
impaired serotonergic neurotransmission19,21. Translation
initiation of the Nfkbia mRNA was determined based on its
association with polysomes using sucrose density gradients
(Fig. 5a). In Eif4e ki/ki mice, the association of Nfkbia mRNA
with the heavy polysome fractions is decreased in cortico-
hippocampal tissue (including mPFC), consistent with a reduc-
tion in the translation of this mRNA in the brain (Fig. 5b). As a
control, the distribution of the Actb mRNA was not changed
(Fig. 5c), and total levels of Nfkbia mRNA were the same in
control versus Eif4e ki/ki mice (Fig. 5d). To demonstrate that the
altered polysome proﬁle of the Nfkbia mRNA resulted in reduced
amounts of IκBα protein, we used Western blotting to measure its
levels in the mPFC. In Eif4e ki/ki and Mnk1/2−/− mice, IκBα
levels were decreased (by 50.88 ± 23.11 % and 33.33 ± 12.44 %,
respectively) as compared to their corresponding littermate
controls (Fig. 5e, f). Taken together, these results demonstrate
dysregulated mRNA translation of IκBα in the mPFC upon
inhibition of eIF4E phosphorylation.
To investigate the pathophysiological consequence of the
decrease in IκBα, we used a multiplex immunoassay to determine
the baseline levels of 23 cytokines, which are known to be
regulated by IκBα/NF-κB, from the PFC of Mnk1/2−/− and Eif4e
ki/ki mice (Supplementary Table 1). Only eotaxin and tumor
necrosis factor α (TNFα) appeared increased in the PFC of both,
Mnk1/2−/− and Eif4e ki/ki mice. We could not detect a difference
in eotaxin levels from independent PFC samples using ELISA
(Supplementary Fig. 6a), although it was reduced in plasma
samples of Mnk1/2−/− and Eif4e ki/ki mice (Supplementary
Fig. 6b). In contrast, TNFα levels were increased in the PFC of
Eif4e ki/ki and Mnk1/2−/− mice by 101.9 ± 42.75% and 178.34 ±
55.33 % over controls, respectively (Fig. 5g and Supplementary
Fig. 6c). Consistent with transcriptional regulation of Tnf, its
mRNA levels were increased in the PFC of Eif4e ki/ki by 104.3 ±
46.83 % over control levels (Fig. 5h). In the circulation, TNFα
levels were elevated only in Mnk1/2−/− (by 203.8 ± 91.62 %), but
not in Eif4e ki/ki mice (Supplementary Fig. 6d, e). Furthermore,
levels of the soluble TNF receptor 1 (sTNFR1) were induced in
the serum of Eif4e ki/ki mice (Supplementary Fig. 6f).
sTNFR1 stabilizes TNFα and its biological activity, thus
promoting inﬂammation43.
Next, we investigated whether increased TNFα led to
neuroinﬂammation. To this end, we measured the levels of Iba1
(Aif1) mRNA, a marker of microglial activation44. We observed
increased levels of Iba1 in the PFC (99.02 ± 33.31 % over control)
(Fig. 5i), and in the hippocampus (100.28 ± 34.73 % over control)
of Eif4e ki/ki mice (Supplementary Fig. 6g). Next, we challenged
Eif4e+/+and ki/ki mice with the immunogen, lipopolysaccharide
(LPS, IP, 2.5 mg kg−1,), and analyzed the brains of the mice 48 h
later; a timeline whereby acute inﬂammatory responses have
receded, but depression-like behaviors persist45. Eif4e ki/ki mice
had more Iba1+ cells in the prefrontal cortex (Fig. 5j, k), and the
hippocampus (Supplementary Fig. 6h, i) following both saline
and LPS treatments. Furthermore, Il1b mRNA was induced to
greater levels in the Eif4e ki/ki mice compared to wild-type
counterparts 48 h after LPS stimulation (145.42 ± 47.84%
over Eif4e+/+treated with LPS) (Fig. 5l). Taken together, these
results demonstrate that inhibition of eIF4E phosphorylation
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causes reduced translation of the Nfkbia mRNA, leading to
increased levels of TNFα expression and an inﬂammatory state in
the brain.
TNFα mediates depression-like phenotypes in Eif4e ki/ki mice.
To investigate the contribution of the elevated brain levels of
TNFα in Eif4e ki/ki and Mnk1/2−/− mice towards the behavioral
and serotonergic alterations, we treated mice with a dominant
negative mutant of TNFα (DN TNF, XPro159546). Central
administration of DN TNF (ICV, 12 days, 10 mg ml−1 in 100 μl,
0.25 μl h−1) effectively reduced the increased immobility in the
FST for the Mnk1/2−/− (Supplementary Fig. 7a) and Eif4e ki/ki
mice (Fig. 6a) by 48.78 ± 13.59 and 59.20 ± 16.69 s, respectively, to
levels indistinguishable from saline-treated control mice. DN
TNF also reduced immobility in female Eif4e ki/ki by 57.59 ±
17.98 s (Fig. 6d). Importantly, the treatment did not affect FST
immobility in wild-type littermates (Supplementary Fig. 7a and
Fig. 6a, d). Furthermore, centrally administered DN TNF
decreased the incremented latency to feed in the NSF test in
Mnk1/2−/− (Supplementary Fig. 7b) and Eif4e ki/ki mice
(Fig. 6b), by 268.0 ± 75.31 and 95.50 ± 39.72 s, respectively, to
levels similar to wild-type controls. The latency to feed in the
home cage was not affected by the DN TNF treatment in neither
wild-type nor mutant mice (Supplementary Fig. 7c and Fig. 6c).
Decreased exploration of the center of the open ﬁeld was
increased in female Eif4e ki/ki mice (Fig. 6e), but not general
locomotion (Fig. 6f).
Moreover, 5-HT-induced excitatory synaptic activity in layer V
pyramidal neurons was restored in male and female Eif4e ki/ki
mice following direct treatment with DN TNF (200 ng ml−1, 1 h
incubation) of the mPFC slices (Fig. 7a–c). The same treatment
did not change the 5-HT-induced increase in sEPSC frequency
(Fig. 7a, c) or amplitude (Supplementary Fig. 2g) in wild-type
mice. Finally, in vivo treatment with DN TNF restored the ﬁring
rate of the DR neurons in Eif4e ki/ki mice to control levels in vivo
(Fig. 7e).
To demonstrate that TNFα causes deﬁcits in 5-HT neuro-
transmission, as it does for behavior47, we determined the 5-HT
response of layer V PFC neurons in wild-type mice following
direct TNFα treatment to the slices (10 ng ml−1, 1 h). TNFα
treatment ameliorated the 5-HT-induced increase in sEPSC
frequency in male and female mice (Fig. 7a, c) without affecting
their amplitude (Supplementary Fig. 2g). In vivo, an acute
treatment with TNFα (ICV, 0.02 fg µl−1) also elicited a rapid
decrease in the frequency of spontaneous ﬁring rate of DR
neurons in wild-type mice (Fig. 8a–c). These results support the
conclusion that over-expression of TNFα is necessary and
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sufﬁcient to induce depression-like behavior and impaired
serotonergic neurotransmission as a consequence of decreased
eIF4E phosphorylation.
To better understand the link between TNFα-induced deﬁcits
in 5-HT neurotransmission in DR and mPFC, we determined the
effects of acute TNFα or DN TNF treatments in the mPFC
(Fig. 8d) on despair-like behavior and DR ﬁring. Acute infusion
of TNFα in the mPFC of wild-type mice (0.1 fg in 0.5 µl of ACSF)
rapidly induced immobility in the FST (Fig. 8f) and a decreased
ﬁring of DR 5-HT neurons (Fig. 8e). However, acute DN TNF
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administration to the mPFC of Eif4e ki/ki mice (100 pg in 0.5 μl
of ACSF), which restores the 5-HT-induced sEPSC excitation in
the mPFC (Fig. 7b, d), failed to rescue the immobility in the FST
(Fig. 8h) and did not inﬂuence the DR 5-HT ﬁring (Fig. 8g).
Finally, acute TNFα infusion in the DR (Fig. 8i) of wild-type
mice, also induced immobility in the FST (Fig. 8k) and decreased
DR 5-HT neuronal ﬁring (Fig. 8j). Like treatment to the mPFC,
acute DN TNF microinjection to the DR did not rescue the
increased FST (Fig. 8n) nor did it diminish the ﬁring rate of DR
5-HT neurons in Eif4e ki/ki mice (Fig. 8l). These results show that
in the Eif4e ki/ki mice, TNFα simultaneously targets the mPFC
and DR to engender the decrease in function of the bidirectional
mPFC-DR circuit48, leading to despair-like behavior.
Discussion
We demonstrated that in mice, a deﬁcit in eIF4E phosphorylation
triggers depression and anxiety phenotypes (Figs. 1, 4 and Sup-
plementary Fig. 1), as well as reduced activity of DR neurons and
impaired serotonin neurotransmission in the PFC (Figs. 2, 4 and
Supplementary Fig. 3 and 4). These effects coincided with a
reduction in brain levels of the NF-κB inhibitor, IκBα, leading to
over production of TNFα, and hypersensitivity to the sequelae of
inﬂammatory stimuli (Fig. 5 and Supplementary Fig. 6). Brain-
wide blocking of TNFα diminished depressive behaviors and
rescued the impairment in serotonergic neurotransmission
(Figs. 6, 7 and Supplementary Fig. 7). Based on these ﬁndings, we
offer a model (Supplementary Fig. 8) whereby reduction of eIF4E
phosphorylation contributes to the development of depressive
symptoms and 5-HT dysfunction by modulating the inﬂamma-
tory response through the translational control of IκBα
expression.
Clinical and preclinical data support a strong link between
inﬂammation and mood disorders. First, the levels of cytokines,
including TNFα and IL-6, are increased in MDD patients22,23, as
well as in individuals that have suffered childhood trauma and
abuse49, a well-documented risk factor for MDD and other
mental disorders50. Second, these observations have been repli-
cated in rodent models of depression induced by chronic
stress51,52. Third, infection-triggered sickness behaviors, which
are similar to symptoms of depression, can be treated with clas-
sical antidepressants45,53. Fourth, clinical trials suggest that non-
steroidal anti-inﬂammatory drugs (NSAIDs) are beneﬁcial for
depression54, as well as anti-cytokine therapies, including those
using blocking antibodies to target TNFα55.
Our ﬁndings support the important role that the NF-κB
pathway plays in the pathophysiology of depressive phenotypes
through the control of serotonergic neurotransmission19. In
this regard, chronic stress can also increase the sensitivity of
NF-κB activation to inﬂammatory stimuli in the PFC and
hippocampus. This occurs via the glucocorticoid receptor, and
can be reversed by MK-80156, an NMDA receptor antagonist
with anti-depressant activity like ketamine57. Furthermore, the
IκB Kinase (IKK) in the nucleus accumbens (NAc) plays an
important role in controlling mood58 and mediating the effects of
chronic social stress in synaptic morphology and in the beha-
vioral expression of social defeat59. IKKs lie directly upstream of
IκBα and are responsible for its phosphorylation and degradation,
leading to NF-κB activation and nuclear translocation60. Activa-
tion of NF-κB by chronic stress is also responsible for the stress-
induced decrease in neurogenesis in the hippocampus and
anhedonia61. Importantly, in humans, it was reported that social
stress increases NF-κB signaling in peripheral blood mononuclear
cells of healthy subjects62 and this response is exaggerated in
depressed patients63.
Targeting the NF-κB signaling pathway for the treatment of
depression has the potential drawback of affecting a myriad of
immune functions60, as well as impairing normal neuronal phy-
siology and cognition64,65. In contrast, targeting TNFα would be
more appealing in light of its role in the pathophysiology of
depression, particularly deﬁcits in serotonin neurotransmission21.
A meta-analysis of clinical data suggests that blocking antibodies
against TNFα are consistently effective in improving mood in
patients with chronic inﬂammatory diseases independently from
the outcome of their accompanying physical illness55.
While the current study was being considered for publication, a
different research group reported depression-like behaviors and
increased inﬂammatory responses in the Eif4e ki/ki mice66.
Behavioral phenotypes in our Eif4e ki/ki mouse testing are con-
sistent with those reported by reference66. In addition, our study
demonstrated the involvement of MNK1 and MNK2 as the
upstream kinases of eIF4E, and demonstrate the involvement of
TNFα as a mediator of serotonergic neurotransmission impair-
ment in the PFC and the DR, as a consequence of decreased
eIF4E phosphorylation and attenuated translation of the mRNA
encoding IκBα.
In summary, we demonstrated that decreased mRNA transla-
tion via inhibition of eIF4E phosphorylation regulates inﬂam-
matory responses via IκBα translation and induction of TNFα in
mice, eliciting an inﬂammatory state, deﬁcits in 5-HT neuro-
transmission and a depressive state that is clinically relevant to
MDD.
Methods
Mice. Adult male and female mice (P60-180) were used in these studies. Mnk1/2
double knockout and Eif4e ki/ki mice have been reported11,12. Mice were housed in
groups of 2–5 per cage with ad libitum access to food and water (except in
experiments involving food deprivation), in temperature (21 °C) and humidity
(~55%) controlled rooms, and a 12, h light/dark cycle. All procedures followed the
Canadian Council on Animal Care guidelines and were approved by McGill
University and Université de Montréal Animal Care Committees.
Behavioral procedures. Mice were handled once 24 h before each experiment. All
behavioral experiments were performed between 10:00 am and 3:00 pm. Behaviors
(except for the open ﬁeld) were recorded, stored, and analyzed as MPEG ﬁles using
an automated behavioral tracking system (Videotrack, View Point Life Science,
Montreal, Canada) equipped with infrared lighting-sensitive CCD cameras. The
Fig. 8 Simultaneous inhibition of mPFC and DR by TNFα underlies despair-like behavior. a Acute recombinant mouse TNFα (ICV, 0.02 pgml−1) into wild-
type mice. b Firing rate of DR neurons in wild-type mice treated with either artiﬁcial cerebrospinal ﬂuid (ACSF) (n= 4) or mouse recombinant TNFα
(n= 6) averaged in 5minute bins. c Representative integrated ﬁring rate histograms (spikes per 10 s) showing traces of DR neurons in wild-type mice
treated with either saline or mouse recombinant TNFα. d Acute treatment of TNFα (0.1 fg in 0.5 µl ACSF) into the mPFC of wild-type mice or DN TNF (100
pg in 0.5 μl ACSF) to Eif4e ki/ki mice. d Firing rate of DRN 5-HT neurons of wild-type mice treated with ACSF (n= 6) or TNFα (n= 6) into the mPFC.
e Immobility time in the FST, 20min after ACSF (n= 6) or TNFα (n= 7) into the mPFC of wild-type mice. f, Firing rate of DRN 5-HT neurons of Eif4e ki/ki
mice treated with ACSF (n= 5) or DN TNF (n= 5) into the mPFC. g FST immobility time 20min after ACSF (n= 6) or DN TNF (n= 7) into the mPFC of
Eif4e ki/ki mice. h Similar treatments were performed into the DRN. i 5-HT DR neuron ﬁring rate after ACSF (n= 7) or TNFα (n= 6) in wild-type mice.
j Despair-like behavior in wild-type mice treated with ACSF (n= 6) or TNFα (n= 10). k DRN 5-HT neurons in Eif4e ki/ki treated with ACSF (n= 5) or DN
TNF (n= 4). l FST immobility in Eif4e ki/ki treated with ACSF (n= 8) or DN TNF (n= 12). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. wild-type ACSF (see
Supplementary Table 2 for detailed results of statistical tests)
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analog signals supplied by the camera were measurements of the luminosity of each
point of the image scanned point-by-point and line-by-line at a rate of 25 images
per second. The signals were transmitted to the Videotrack system and digitized on
8 bits by digital analog conversion. Before the experiments, animal/image back-
ground contrast detection thresholds were calibrated by visual inspection to dis-
tinguish different behavioral patterns.
For the forced swim test, mice were placed in a glass beaker (24 cm tall, 14 cm
diameter) containing 3 L of water at 24 ± 2°C. Mice were allowed to swim for 6
minutes. Immobility was quantiﬁed in the last 4 minutes of the test using the
Videotrack system.
For the tail suspension test, mice were suspended by their tail from a lever in a
30 × 30 × 30 cm white-painted enclosure. Movements were recorded and quantiﬁed
for 5 min in a dimly lit environment.
For the novelty suppressed feeding, mice were food-deprived for 48 h, then each
mouse was placed in a brightly illuminated (100W, 350 lx) open arena (40 × 40
white-painted ﬂoor with white walls 30 cm in height) containing lab chow (3
pellets) placed at the center of the arena. The latency to initiate feeding (in seconds)
was noted and used as an index of anxiety/depression-like behavior. The cut-off
time was 600 s. Feeding latency was also observed in the home cage containing 3
pellets spread on the ﬂoor. The session was terminated immediately after mice had
initiated feeding.
Locomotor activity and time spent in the center of an open ﬁeld were quantiﬁed
for 10 min with an infrared activity-monitoring acrylic apparatus with activity
sensors located on the sides, front, and back of the boxes (VersaMax system,
AccuScan Instruments, Columbus, OH, U.S.A.). Mnk1/2−/− and wild-type
littermates were tested twice in the apparatus, with the second test occurring
1 week after the initial test.
Anti-depressant treatments. Fluoxetine hydrochloride (Tocris Bioscience, Oak-
ville ON, Canada), escitalopram oxalate (Tocris Biosceicne) and ketamine (Nar-
ketan 10, Vetoquinol, Lavaltrie, QC, Canada) were diluted in 0.9% NaCl solution
and administered IP as follows: acute ﬂuoxetine, 1 dose of 3 mg kg‒1 (behavioral
testing/tissue collection occurred 0.5 h after injection); chronic ﬂuoxetine, 14 doses
(daily) of 10 mg kg‒1 (tissue collection occurred 0.5 h after last injection); repeated
citalopram 3 doses of 10 mg kg‒1 (24, 5 and 0.5 h before tissue collection); ketamine
(10 mg kg‒1) 1 or 24 h before behavioral testing/tissue collection or mPFC whole-
cell recordings.
Cercosporamide treatment. Intraperitoneal (i.p.) injections were carried out
using an aqueous solution of 4% Tween 80 (Sigma-Aldrich) and 4% PEG-400
(Sigma-Aldrich). Cercosporamide was administered daily by i.p. injections for ﬁve
consecutive days at 20 mg kg‒1 to 8 week-old C57BL/6 J male mice (Jackson
Laboratory). Mice were tested in the FST 1 h after the last injection and imme-
diately sacriﬁced for brain collection. Other cohorts of wild-type and Eif4e ki/ki
mice were treated likewise and used for layer V mPFC whole-cell recordings or
in vivo DR recordings, 1 h after the last injection.
Mouse serum and brain collection. Naive mice (Mnk1/2−/−, Eif4e ki/ki and their
respective wild-type littermates) were brieﬂy anesthetized using 5% isoﬂuorane.
Blood was collected by heart puncture and allowed to clot for 10 min at 4 °C. Serum
was separated by centrifugation (10 min, 4 °C, 5000 × g) and stored at −80 °C.
Brains were harvested immediately after heart puncture, prefrontal cortex and
hippocampus dissected, ﬂash frozen and kept at −80 °C until used.
In a separate experiment, Eif4e ki/ki and wild-type littermates were treated with
saline (IP, 10 ml kg−1) or LPS (E. Coli 0111:B4, 2.5 mg kg−1 45, Sigma-Aldrich, St
Louis MO, U.S.A.) and sacriﬁced 48 h later45. At that point, brains were harvested
immediately, prefrontal cortex and hippocampus dissected, ﬂash frozen and kept at
−80 °C until used or processed for immunohistochemical analyses.
Polysome proﬁling. Polysome proﬁling was performed as previously reported67.
Brieﬂy, hippocampi and prefrontal cortex were dissected and snap frozen, then
homogenized in 425 μl of hypotonic buffer [(5 mM Tris-HCl (pH 7.5), 2.5 mM
MgCl2, 1.5 mM KCl and 1 × protease inhibitor cocktail (EDTA-free)], with 5 μl of
10 mg/ml cycloheximide, 1 μl of 1 M DTT, and 100 units of RNAse inhibitor. After
homogenization, 25 μl of 10 % Triton X-100 (ﬁnal concentration 0.5 %) and 25 μl
of 10 % Sodium Deoxycholate (ﬁnal concentration 0.5 %) were added. Following a
10 min incubation at 4 °C, samples were centrifuged (16,000 × g for 7 min at 4 °C).
After adjusting for RNA concentration, the supernatant was applied to a 5–50%
sucrose gradient and centrifuged at 222,228 × g (36,000 rpm), for 2 hr at 4 °C.
Gradients were fractionated using an automated collector (Teledyne ISCO Foxy R1
Fraction Collector, Cole Palmer) connected to a syringe pump (Brandel) and a UV
detector (Teledyne ISCO UA, 6 UV/VIS Detector). RNA was extracted from the
collected fractions, along with an input sample, using TRIzol reagent (Ambion by
Thermo Fisher Scientiﬁc). cDNA was then synthesized using Super Script III
reverse transcriptase (Invitrogen by Thermo Scientiﬁc) using 250 ng of RNA as
template and then Nfkiba and Actb mouse speciﬁc TaqMan assays (Applied Bio-
systems by Thermo Fisher Scientiﬁc). mRNA levels were estimated using the ΔΔCt
method.
Bio-Plex Immunoassay. Flash-frozen prefrontal cortex from Eif4e ki/ki,Mnk1/2−/−
and their respective wild-type littermate control mice were lysed using the Bio-Plex
Cell Lysis Kit (Bio-Rad, Mississauga, ON, Canada) following the manufacturer’s
instructions for tissue samples. Samples were assayed in the Bio-Plex Pro mouse
cytokine 23-plex assay following the manufacturer’s instructions. The plate was read
in the Bio-Plex 200 plate reader.
ELISA. Serum or prefrontal cortex lysate (using the Bio-Plex Cell Lysis Kit) were
assayed for eotaxin or TNFα using Quantikine ELISAs for mouse eotaxine or TNFα
(R&D Systems, Minneapolis, MN, U.S.A.) following the manufacturer’s instruc-
tions. Soluble TNF receptor 1 (sTNFRI) was also measured in mouse serum
(Quantikine ELISA, R&D Systems, Minneapolis, MN, U.S.A.)
Real-time qPCR. Flash-frozen prefrontal cortex and hippocampus were processed
for RNA extraction using TRIzol reagent (Ambion by Thermo Fisher Scientiﬁc).
cDNA was then synthesized using Super Script III reverse transcriptase (Invitrogen
by Thermo Scientiﬁc) using 500 ng of total RNA as template and then Tnf, Il1b,
Iba1 (Aif1) and Actb mouse speciﬁc TaqMan assays (Applied Biosystems by
Thermo Fisher Scientiﬁc). mRNA levels were estimated using the ΔΔCt method.
Western Blotting. Mouse tissues were dissociated using Bio-Plex Cell Lysis Kit
(Bio-Rad, Mississauga, ON, Canada). Western blotting was performed as pre-
viously described68. Antibodies against indicated proteins were: phospho-eIF4E
(Ser209, Abcam, 1:1000), eIF4E (BD Biosciences, 1:1000), IκBα (Cell Signaling
Technology, 1:1000), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
coupled to Horseradish Peroxidase, Abcam, 1:5000) or β-actin (Sigma, 1:5000);
secondary antibodies were anti-mouse and anti-rabbit (GE Healthcare). Quantiﬁ-
cation of immunoblots was performed using ImageJ (NIH), and expressed as a
ratio (either p-eIF4E/eIF4E or eIF4E/GAPDH or eIF4E/β-actin, IκBα/GAPDH).
Western blots experiments were replicated at least two times. Uncropped western
blots are provided in Supplementary Figure 9.
Immunohistochemistry. For the analysis of neuroinﬂammation markers, coronal
brain sections were thin cut (50 μm) using a Cryostat and placed in PBS containing
2 mM sodium azide and 3 mM NaF, pH 7.4. For the immunohistochemical
staining, sections were ﬁrst treated with 0.3% H2O2 and 20% methanol in PBS for
10 min to deactivate endogenous peroxidases and permeabilize the tissue, and then
blocked for 1 h in 10% goat serum/PBS and incubated (overnight, 4 °C) in rabbit
anti-IBA1 antibody (1:1000 ﬁnal dilution). Next, tissue was incubated for 1.5 h at
room temperature in biotinylated anti-rabbit IgG (1:200; Vector Laboratories,
Burlingame, CA) and then placed in an avidin/biotin HRP complex for 1 h (pre-
pared per instructions of the manufacturer; Vector Laboratories). Sections were
washed in PBS (three times, 10 min/wash) between each labeling step. The signal
was visualized using nickel-intensiﬁed DAB substrate (Vector Laboratories) and
sections were mounted on gelatin-coated slides with Permount media (Fisher
Scientiﬁc, Houston, TX).
Bright-ﬁeld microscopy images were captured using a digital camera mounted
on an inverted Zeiss microscope (Oberkochen, Germany). All data were quantiﬁed
using Adobe Photoshop software (Adobe Systems Incorporated, San Jose, CA). For
cell counting, an intensity threshold ﬁlter was initially applied to eliminate
nonspeciﬁc background labeling, and then the number of detectable signals above
the threshold (now deﬁned as positive cells) were counted on the 100 ×
micrographs for the hippocampal CA1 area and the prefrontal cortex. A mean
value for each animal was generated from 2 brain sections per animal; this value
was then used to generate the group mean.
For the quantiﬁcation of 5-HT and total number of DR neurons, coronal DR
sections were ﬁxed in 2% paraformaldehyde (10 min, RT) washed in PBS, and then
incubated in 10% normal donkey serum (NDS) and 0.2% Triton X (1 h, RT). Then,
primary antibodies were applied (in 10% NDS, 4 C for 48 h). Antibodies were:
polyclonal rabbit anti-TPH2 (Novus Biologicals, 1:1000) and monoclonal mouse
anti-NeuN (Millipore, 1:150). After washing, avidin/biotin blocking was performed
(Avidin/Biotin blocking kit, Vector Laboratories), then slices were incubated with
Cy3 donkey anti-rabbit (Linaris, 1:400) and biotinylated horse anti-mouse (Biozol,
1:2000, for 2 h, at RT. Following a washing step, FITC-avidin was applied (1:300, 1
h, RT), then DAPI staining performed (1:8000, 10 min, RT) and sections were
cover slipped with Citiﬂuor (Citiﬂuor Ltd.). For image capture and analysis, a
conventional light/ﬂuorescent Olympus BX50 microscope (Olympus Optical,
Hamburg, Germany) with a black and white Spot Insight camera (Diagnostic
Instruments, Visitron systems, Puchheim, Germany) was used. By means of image
editing software (MetaMorph 5.05) the individual images were combined into red/
green/blue color ﬁgure plates and the counting tool was applied for the 4 areas as
indicated; brightness and contrast were adjusted, and the images stored as TIFF
ﬁles (Adobe Photoshop 5.05). All sections were processed the same way to enable
comparison.
For analysis of neurogenesis markers, immunohistochemistry was conducted on
50 µm thick free-ﬂoating sections cut on a freezing sliding microtome. Every 8th
section was sampled for staining through the entire septo-temporal axis of the
hippocampus.
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The following pre-treatment were used prior to immunohistochemistry: for
BrdU staining, sections were ﬁrst incubated in 2 N HCl at 37 °C for 30 min to
denature the DNA; for Ki67, antigen retrieval was performed with heated citrate
buffer (pH= 6.0) in a steamer (95–100 °C) for 15 min, followed by a cool down at
room temperature for 30 additional minutes; no pre-treatment was required for
DCX staining.
For all markers, endogenous peroxidase was quenched in 3% H2O2 in PBS,
followed by blocking (PBS/0.2% Triton x-100/2% normal serum from secondary
antibodies host species) and overnight incubation in primary antibody solution
diluted in blocking buffer at 4 °C (rat anti-BrdU 1:1000, Serotec; mouse anti-ki67
1:2000, Pharmingen; goat anti-DCX 1:1000, Santa Cruz Biotechnology). Sections
were incubated for 1 hr at RT with biotinylated secondary antibodies at 1:200 (goat
anti-rat, horse anti-mouse and horse anti-goat, respectively; Vector Laboratories),
and the reaction was visualized with DAB after avidin-biotin peroxidase complex
ampliﬁcation (Vectastain, Vector Laboratories). Sections were then mounted on
slides, left to dry overnight, dehydrated and coverslipped for stereological analysis.
Cell counting and density measurements were performed with an Olympus
BX51 microscope under a ×40 objective lens and using Stereo Investigator software
(MBF Bioscience). For each marker and in every 8th section, all positive cells within
the mounted thickness of the granule cell layer of the dentate gyrus were counted
blind to the experimental group. For each section, counts were divided by the area
of the dentate gyrus to yield cellular density. Data presented correspond to the
average of 9 sections per animal.
In vivo extracellular recording. In vivo single-unit extracellular recording
electrophysiology experiments were conducted as previously37. Mice were
anesthetized with chloral hydrate (400 mg kg−1 i.p., using a 2% solution) and
placed in a stereotaxic frame (using the David Kopf mouse adaptor) with the skull
positioned horizontally. To maintain a full anesthetic state in which there was no
reaction to a tail or paw pinch, chloral hydrate supplements of 100 mg kg−1
were given as needed. Extracellular single-unit recordings were performed using
single-barreled glass micropipettes pulled from 2mm capillary glass (Stoelting,
Wood Dale, IL, U.S.A.) on a PE-21 pipette puller (Narashige, Tokyo, Japan) and
preloaded with ﬁberglass strands to promote capillary ﬁlling with 2 % Pontamine
Sky Blue dye in 2M NaCl for Dorsal Raphe Nuclei neuronal recordings. The
micropipette tips were broken down to diameters of 1–3 μm to reach an electrode
impedance of 2–6 MΩ.
For microinjection in the DRN, a cannula (33-gauge stainless steel tubing) was
stereotaxically lowered using the following coordinates: AP: −3.42 mm from
bregma; ML: ± 0.0 mm, DV: −1.97 mm from dura, 30° angle. For microinjections
in the mPFC, a similar cannula was lowered at: AP:+ 1.7 mm; ML: ± 2.0 mm; DV:
−2.0 mm, 30° angle. Vehicle (ACSF: 2.5 mM KCl; 125 mM NaCl; 1.18 mM MgCl2;
1.26 mM CaCl2), TNFα (0.1 fg in 0.5 µl ACSF) or DN TNF (200 ng ml−1 in 0.5 ul)
solutions were used to ﬁll the cannula. The microinjection was made using a 5 μl
Hamilton syringe that was connected to the injection cannula by a length of
polyethylene (PE-10) tubing over a period of 60 s and the injection cannula was
gently removed 2 min later.
The single-barreled glass micropipettes were positioned 0.5 to 1 mm posterior
to the interaural line on the midline and lowered into the DRN, attained at a depth
of between 2.5 and 3.5 mm from the brain surface. The DRN 5-HT neurons were
then identiﬁed according to the following criteria: a slow (0.5–2.5 Hz) and regular
ﬁring rate with a long duration (0.8–1.2 ms) and positive action potentials. Single-
unit activity was recorded as large-amplitude action potentials captured by a
software window discriminator, ampliﬁed by an AC Differential MDA, 3 ampliﬁer
(BAK electronics, Umatilla, FL, U.S.A.), post-ampliﬁed and band-pass ﬁltered by a
Realistic 10 band frequency equalizer, digitized by a CED 1401 interface system
(Cambridge Electronic Design, Cambridge, U.K.), processed online, and analyzed
off-line using Spike2 software version 5.20 for Windows. The spontaneous single-
spike activity of neurons was recorded for at least 2 min and 30 s immediately after
detection to eliminate mechanical artifacts due to electrode displacement. The total
number of spontaneously active 5-HT neurons and their ﬁring rates were
determined by monitoring their average discharge frequency for a minimum
period of 1 min. The number of neurons recorded per electrode descent was also
calculated, since the number of neurons recorded is a valid, indirect index of the
percentage of neurons that are spontaneously discharging (active) during in vivo
electrophysiological recordings69.
Intracerebroventricular (ICV) TNFα injection. For ICV implantation, mice
were anesthetized with chloral hydrate and placed in a stereotaxic frame with
the skull positioned horizontally. Burr holes were drilled in the skull on the side
over one of the lateral ventricle and a guide stainless steel cannula (26 gauge)
was stereotaxically lowered 2.5 mm using the following coordinates: AP: −0.2 mm
from bregma, L: ± 0.9 from the midline and V: −2.5 mm from cortical surface.
The cannula was ﬁxed into the skull using dental screws and cement. A vehicle
(ACSF: 2.5 mM KCl; 125 mM NaCl; 1.18 mM MgCl2; 1.26 mM CaCl2) or
recombinant mouse TNFα (R&D System) (0.1 fg in 5 µl ACSF) solution preﬁlled
inner cannula (33-gauge stainless steel tubing) was inserted and driven 0.5 mm
below the tip of the guide. The microinjection was made using a 5 μl Hamilton
syringe that was connected to the injection cannula by a length of polyethylene
(PE-10) tubing over a period of 60 s and the injection cannula was gently removed
2 min later.
Whole cell recordings in PFC slices in vitro. Eif4e ki/ki and wild-type littermate
mice (6–8-week-old) received intraperitoneal injections of ketamine (IP, 10 mg kg‒1)
or saline 24 h before whole cell recording experiments. Serotonin creatine sulfate
monohydrate (5-HT; 20, 50 or 100 µM; from Sigma) was freshly prepared in aCSF.
Recombinant mouse TNF-α (R&D Systems) was dissolved in phosphate buffer
containing 0.1% bovine serum albumin as stock solution (1000 × ﬁnal concentra-
tion) and kept at ‒20 °C. The dominant-negative (DN) TNF, XPRO1595 (from
Xencor), was freshly prepared in phosphate buffer. DN-TNF (200 ng ml‒1) and
TNF-α (10 ng ml‒1) were freshly prepared in aCSF and slices were pre-incubated
for 60 min before recording.
For brain slice preparation, Eif4e ki/ki and wild-type littermate mice (6 to
8-week-old) were anesthetized with isoﬂurane and the brain was removed and
placed in ice-cold oxygenated (95% O2 / 5% CO2) cutting solution containing
87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 7 mM MgSO4, 25 mM NaHCO3,
25 mM D-glucose, 75 mM sucrose, 1 mM ascorbic acid, 3 mM pyruvic acid and
0.5 mM CaCl2. Coronal slices (300 μm thickness) of medial prefrontal cortex were
prepared using a Vibratome (Leica; VT1000S) and transferred to oxygenated
artiﬁcial cerebrospinal ﬂuid (aCSF) containing 124 mM NaCl, 5 mM KCl, 1.25 mM
NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM NaHCO3 and 10 mM dextrose
(pH= 7.3–7.4; 295-300 mOsmol) at room temperature. After a recovery period of
at least 60 min, individual slices were transferred to a submersion recording
chamber mounted on an upright microscope (Zeiss, Oberkochen, Germany)
equipped with a long-range water immersion objective (40 ×) with Hoffmann
optics (Modulation Optics, Greenvale, NY) and an infrared CCD camera, and
perfused at 2.5 ml min‒1 with aCSF at 32 °C.
Recordings were obtained from layer V pyramidal cells under visual
guidance using patch pipettes (3-5 MΩ) pulled from borosilicate glass capillaries
(World Precision Instruments, Sarasota, USA) and ﬁlled with solution
containing 120 mM CsMeSO3, 5 mM NaCl, 1 mM MgCl2, 10 mM di-Na-
phosphocreatine, 10 mM HEPES, 2 mM ATP, 0.5 mM GTP, 2 mM QX314, 0.5 mM
spermine and 0.3 % biocytin (pH 7.3; 285-295 mOsmol). Excitatory postsynaptic
currents (EPSCs) were recorded in voltage-clamp mode using a Multiclamp 700 A
ampliﬁer (Molecular Devices) and digitized using Digidata 1440 A and
pClamp10 software (Molecular Devices). Recordings were low-pass ﬁltered at 2
kHz, digitized at 20 kHz and stored on a PC. Series resistance (15–25 MΩ) was
regularly monitored during experiments and only cells with series resistance
changes less than 20 % of initial value and stable holding current were included.
Spontaneous EPSCs were recorded at −70 mV holding potential before, during,
and after bath application of 5-HT (20 µM; 3 min application), and analyzed ofﬂine
with Mini Analysis Version 6.0.3 software (Synaptosoft Inc., Decatur, GA, USA)70.
The detection threshold of spontaneous EPSCs was set at twice baseline noise level
and individual events were conﬁrmed by visual inspection. Only cells that exhibited
stable sEPSC frequency and amplitude over a 10 min control period were kept and
only one cell was recorded per slice. After completion of recordings, slices were
transferred to 4% paraformaldehyde (0.1 M phosphate buffer) and stored overnight
at 4 °C. Slices were then processed using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) and observed under a light microscope.
Experimenter was blind to the mice genotype and codes were broken after data
analysis.
Statistical analyses. Data were expressed as mean ± S.E.M. and analyzed using
GraphPad Prism 6 (GraphPad Software Inc.). Statistical results are detailed in
Supplementary Table 2. When comparing two data sets, (Figs. 2d, i, 4c, d, 5d, i, 8f,
h, k, n, Supplementary Figs. 1a, b, 3c, d, 6a–g) unpaired Student’s t-test were
performed; when variance was signiﬁcantly different between groups, Welch’s
correction was used. One-way ANOVA was used for data in Fig. 3c, d. Data sets
depicted in Figs. 1a–j, 3a, b, 4g, 5j, l, 6a–f, 7e, Supplementary Figs. 3a, 4f–h, 5a, 5c,
5e, 6h, and 7a–c were analyzed using two-way ANOVA, with genotype and gender
(Fig. 1a, j, Supplementary Figs. 5a, c, e) or treatment (Figs. 3a, b, 4g, 5j, l, 6a–f, 7e,
Supplementary Figs. 4f–h, 6h, 7a–c) as independent factors; when interaction was
signiﬁcant, Bonferroni pair-wise comparisons were used. Data from Figs. 2b, 4f, 7c,
d, 8b, 8e, g, j, l and Supplementary Figs. 1c–f, 2a–c, 2f, g, 3a, b and 4b–e were
analyzed using mixed-design two-way ANOVA with genotype (Fig. 2b, Supple-
mentary Figs. 1c–f, 2a–c, 3a, b and 4b–e) or treatment (Figs. 4f, 7c, d, 8b, e, g, j, l,
and Supplementary Figs. 2f, g) as independent factor, and pre- post- 5-HT
(Figs. 2b, 4f, I, j, Supplementary Figs. 2a–c, 2f, g and 4b–e), time after treatment
(Figs. 8b, d, f, i, k), testing session (Supplementary Figs. 1c–f) or drug dose
(Supplementary Fig. 3a, b) as repeated measure; Bonferroni was used for pair-wise
comparisons when interaction was signiﬁcant. Values of p < 0.05 were considered
signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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